---
tags:
aliases:
---
21-09-2025

# What Did I learn?


actionable therapeutic target

Anaplastic

in Anaplastic Thyroid Carcinoma DABRAFENIB and MEK inbitor TRAMETINIB is an FDA-approved regimen
can prolong survival more than 1 year
as we can target BRAF, they have better prognosis than negative patients

Papillary
in ADVANCED, targeted therapy can be used

[[BRAF V600E - Mechanism and Prevalence in Thyroid Cancer]]




